Document Detail

Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer.
MedLine Citation:
PMID:  23288345     Owner:  NLM     Status:  Publisher    
Lymphatic invasion (LVI) is associated with disease recurrence in axillary node-negative (ANN) breast cancer. Using gene expression profiling of 105 ANN tumors, we found that podocalyxin (PODXL) was more highly expressed in tumors with LVI (LVI+) than in those without LVI (LVI-). Differences in PODXL expression were validated using real-time polymerase chain reaction as well as by immunohistochemistry in an independent set of 652 tumors on tissue microarrays. Disease-free survival (DFS) analyses were conducted for association of high PODXL protein expression with risk of distant recurrence overall and within breast cancer subtypes using both Cox and cure-rate models. High PODXL expression was associated with poor prognosis features including large tumor size, high histological grade, estrogen and progesterone receptor negativity, and with clinical alterations characteristic of the basal-like breast cancer phenotype. Surprisingly, despite having other poor prognosis characteristics, women with high PODXL expressing tumors had better long-term DFS in multivariate analysis with traditional clinicopathologic factors including LVI and HER2 status (P = 0.001). PODXL has the potential to be a useful biomarker for identifying good prognosis patients in characteristically poor prognosis breast cancer groups and may impact treatment of women with this disease.
Catherine L Forse; Yildiz E Yilmaz; Dushanthi Pinnaduwage; Frances P O'Malley; Anna Marie Mulligan; Shelley B Bull; Irene L Andrulis
Related Documents :
23572855 - Criteria and procedures for breast conserving surgery.
24619745 - Triple-negative breast carcinoma: current and emerging concepts.
24771895 - Biological matrices and synthetic meshes used in implant-based breast reconstruction - ...
23357705 - Challenges in the management of pleomorphic lobular carcinoma in situ of the breast.
20110775 - Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanis...
21390495 - Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-4
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  -     ISSN:  1573-7217     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Fred A. Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, ON, M5G 1X5, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outc...
Next Document:  A systematic review of elastography, electrical impedance scanning, and digital infrared thermograph...